Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sitaxsentan trial completed, extension ended

After market close, Icos-Texas Biotechnology said it completed enrollment of 180 patients in a North America Phase IIb/III STRIDE trial of

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE